Serina Therapeutics (SER) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ platform, which enhances efficacy and safety of small molecules, RNA-based therapeutics, and antibody-drug conjugates.

• Recently completed a merger and rebranded, with common stock now trading on NYSE American under the symbol "SER."

Financial performance and metrics

• Most recent audited financial statements as of December 31, 2024, are incorporated by reference, with an explanatory paragraph regarding the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, research and development, business expansion, strategic transactions, and general corporate purposes; specifics for each offering will be detailed in the relevant prospectus supplement.